Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Women's Health Initiative (WHI)

Trial Profile

Women's Health Initiative (WHI)

Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Conjugated estrogens (Primary) ; Conjugated estrogens/medroxyprogesterone (Primary) ; Calcium/colecalciferol
  • Indications Bone disorders; Breast cancer; Cardiovascular disorders; Colon cancer; Coronary disorders; Menopausal syndrome; Myocardial ischaemia; Postmenopausal osteoporosis; Stress incontinence
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results of pooled analysis of this and other trial assessing long term all cause and cause specific mortality, published in the JAMA: the Journal of the American Medical Association.
    • 02 Dec 2016 Results (n=1521) assessing efficacy of calcium + Vitamin D + Hormone therapy on cardiovascular disorders, published in the Obstetrics and Gynecology
    • 27 Mar 2012 Tolerability results assessing the incidence of atrial fibrillation in WHI-E and WHIHRT trials presented at the 61st Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top